News Center

位置：

Honors Announcement

Group News

Media Reports

Shijiazhuang Sihua Pharmaceutical Group Achieves a Strong Start in the First Quarter

Category:

Group News

发布时间：2022-04-09

【概要描述】 Good news has emerged from Shijiazhuang Sihua Pharmaceutical Group: in the first quarter of this year, both the company’s total industrial output value and sales revenue posted double-digit year-on-year growth, delivering a strong start to the year and sustaining its steady development momentum.

Shijiazhuang Sihua Pharmaceutical Group Achieves a Strong Start in the First Quarter

With the arrival of spring and the bright, serene weather, all things are flourishing. In tune with the rhythm of the season, Shijiazhuang No. 4 Pharmaceutical Group has announced encouraging news: in the first quarter of this year, both the company’s total industrial output value and sales revenue posted double-digit year-on-year growth, delivering a strong start to the year and sustaining its steady development trajectory.

Stepping into the intravenous solution manufacturing workshop of Shijiazhuang Sihua Pharmaceutical in the High-tech Industrial Development Zone, one is greeted by a bustling scene of employees at work. Robotic arms perform intelligent operations on the packaging line, and automated equipment hums cheerfully—every corner exudes the vibrant energy of spring.

“Since the beginning of this year, we have firmly embraced the principles that ‘the market comes first’ and ‘efficiency is paramount,’ closely aligning our strategies with market dynamics. Through flexible, diversified, and robust initiatives, we have vigorously advanced national and tiered centralized procurement programs, clinical development, and the expansion into various end-user markets, accelerated the penetration of previously untapped segments, deeply unlocked market potential, shifted our focus downward to capture greater share in the primary-care segment, and strategically positioned ourselves to secure a leading foothold in grassroots healthcare sales,” said Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical. He added that more than 20 newly approved products from Sihua last year are now in full-scale production, many of which boast compelling value propositions in terms of indications, cost-effectiveness, and accessibility. For instance, the newly launched terbutaline inhalation solution has quickly become a highly sought-after product since its launch this year, while sales of newly included items in the national centralized procurement program have experienced exponential growth in the first quarter, giving us a decisive head start in achieving a strong opening performance for the quarter.

In the first quarter, Sihua Pharmaceutical enjoyed a string of R&D breakthroughs, securing approval for nine new specialty formulations and active pharmaceutical ingredients, placing the company among the industry leaders in both R&D progress and the number of approvals obtained. “We focus on the products most in demand and most urgently needed by the market, intensifying our efforts to develop pioneering new products. By aligning our R&D initiatives with market dynamics and competitive pressures, we are accelerating the efficiency of new-product development, regulatory submission, and technology transfer, thereby leveraging innovation to drive the Group’s high-quality growth,” said Su Xuejun. He added that the company is stepping up its strategic deployment in antiviral, antibacterial, central-nervous-system, oncology, cardiovascular, and anesthesia therapeutic areas, with nearly 200 new products currently under development and more than 60 awaiting approval. In the first quarter alone, nine new product approvals were secured, and this diversified, innovation-driven portfolio is providing robust momentum for Sihua Pharmaceutical to accelerate its journey toward high-quality development.

In terms of project construction, Siyao spares no effort. At the construction site of the New Formulation and Biopharmaceutical Industrial Park project of Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Siyao Group located in the Shijiazhuang Economic and Technological Development Zone, several tower cranes are busily swinging their booms overhead, while bulldozers and excavators rumble on the ground, creating a new symphony of “accelerated progress.” The entire project is now well underway. Zhao Yongzheng, Executive President of Siyao and Chairman of Guolong Pharmaceutical, stated: “To ensure the early commissioning of the project, we have been working overtime, with all employees brimming with enthusiasm and unwavering confidence.” Currently, Siyao has six key technological transformation projects under construction, which will strongly propel the company’s industrial restructuring toward modernization, intelligent manufacturing, and high-end production.

“Going forward, we will continue to increase our investment in innovation, accelerate the development and implementation of high-end industrialization projects, make all-out preparations for the seventh round of national centralized procurement bidding, pioneer market development initiatives that are both forward-looking and highly catalytic, and strive to achieve “more than half” in both revenue and profit for the second quarter. In doing so, we aim to help the city’s biopharmaceutical industry take the lead in achieving breakthroughs, build a cluster worth hundreds of billions of yuan, and contribute to the early realization of a city-wide economic output exceeding one trillion yuan—thus fulfilling Shijiazhuang Sihua Pharmaceutical Group’s commitment.”

Keywords:

Liu Hao, Executive Vice Mayor of Taizhou City, Conducts a Research Visit to Bosheng Company of the Group

Wang Jinshan, Secretary of the CPC Gaocheng District Committee, Conducts Research and Inspection at Shijiazhuang No. 4 Pharmaceutical Group

Liu Hao, Executive Vice Mayor of Taizhou City, Conducts a Research Visit to Bosheng Company of the Group

Wang Jinshan, Secretary of the CPC Gaocheng District Committee, Conducts Research and Inspection at Shijiazhuang No. 4 Pharmaceutical Group